- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
This study is testing new medicines, DFV890 and MAS825, for adults with heart disease and a blood condition called CHIP. We want to see if these medicines can lower inflammation and if they are safe. Some people will get a dummy treatment (placebo) for comparison.
For: Atherosclerotic cardiovascular diseaseGermany - Active not recruitingPHASE2
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
This study is testing a new medicine called MAS825 for rare conditions like NLRC4-GOF, XIAP deficiency, and CDC42 mutations. It aims to see if the medicine is safe and helps patients feel better, compared to a dummy medicine, over several years.
For: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 MutationsUnited States · Czechia · France